Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR)

Phase 2

Not yet recruiting

• Conditions: Relapsed or Refractory DLBCL
• Interventions: Drug: Anti-PD-1 Antibody Plus Chidamide and Rituximab

• Registration Number: NCT05115409
• Lead Sponsor: Sun Yat-sen University

Brief Summary

To assess the efficacy and safety of Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in the Treatment of Relapsed or Refractory DLBCL

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-11-09
• Study First Submitted QC: 2021-11-09
• Study First Posted: 2021-11-10
• Status Verified: 2022-04
• Last Update Submitted: 2022-04-06
• Last Update Posted: 2022-04-07
• Study Start: 2022-06-01
• Primary Completion: 2022-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 27

Inclusion Criteria

• Male or female patients: 60-75 years old.

• Relapsed or Refractory patients

• Histologically confirmed DLBCL with CD20 positive

• ECOG physical condition score: 0-1 points for patients.

• The patients must be with at least one evaluable or measurable lesion meeting LYRIC 2016 criteria.

• Patients who had received at least 2 cycles of standard first-line rituximab regimens didn't obtain remission or relapsed after remission, or who were unable or unwilling to receive chemotherapy due to illness or severe chemotherapy toxicity.

• Hematology values must be within the following limits at baseline:

  1. Absolute neutrophil count (ANC) ≥1,500 cells/μL. In case bone marrow involvement, ANC≥1,000 cells/μL.
  2. Platelets≥75,000 cells/μL. In case bone marrow involvement, platelets≥50,000 cells/μL
  3. Hemoglobin≥90 g/L.In case bone marrow involvement, hemoglobin≥70 g/L

• Biochemical values must be within the following limits at baseline:

  1. Alanine aminotransferase#ALT#≤2.5×upper limit of normal (ULN).
  2. Aspartate aminotransferase (AST) ≤2.5×ULN
  3. Total bilirubin≤1.5×ULN, unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin.
  4. Serum creatinine ≤2×ULN.

• LVEF ≥50%, as determined by echocardiography.

• Each subject (or their legally acceptable representative) must sigh an informed consent form (ICF) indicating that he or she understands the purpose of any procedures for the study and are willing to participate in the study.

• Thyroid stimulating hormone (TSH) or free Thyroxine (FT4) or free Triiodothyronine (FT3) were within the normal range of ±10%.

• Expected survival time ≥6 months.

• No radiotherapy, chemotherapy, targeted therapy or hematopoietic stem cell transplantation within 4 weeks before medication.

Exclusion Criteria

• Patients with clinically symptomatic CNS metastases (e.g., cerebral edema, need for hormonal intervention, or progression of BRAIN metastases) and/or cancerous meningitis.
• A history of severe allergies or allergic reactions to drugs mentioned above.
• Patients with other malignant tumors have undergone radical treatment, except for basal cell carcinoma of skin, squamous cell carcinoma of skin, carcinoma in situ of breast and carcinoma in situ of cervix.
• History of human immunodeficiency virus (HIV) infection and/or patients with acquired immunodeficiency syndrome.
• Patients with active hepatitis B or active hepatitis C. Patients who are positive for hepatitis B Surface Antigen (HBsAg) or hepatitis C Virus (HCV) antibodies at screening stage must pass further detection of hepatitis B Virus (HBV) DNA titer (no more than 2500 copies/mL or 1000 IU/mL) andHCV RNA (no more than the lower limit of the detection method) in the row. In addition to active hepatitis B or hepatitis C infections requiring treatment, group trials can be conducted. Hepatitis B carriers, stable hepatitis B (DNA titer should not be higher than 2500 copies/mL or 1000 IU/mL) after drug treatment, and cured hepatitis C patients can be enrolled in the group.
• Inability to swallow, intestinal obstruction, or other factors that affect drug administration and absorption.
• Received systemic antineoplastic therapy within 28 days before treatment, including chemotherapy, immunotherapy, biotherapy (cancer vaccine, cytokines, or growth factors that control cancer), etc..
• Received major surgery within 28 days before treatment or radiotherapy within 90 days before treatment.
• Received live vaccination (except influenza attenuated vaccine) within 28 days before treatment.
• Patients requiring long-term systemic glucocorticoid therapy or other immunosuppressive therapy. Allowing subjects to use local, ocular, intra-articular, intranasal and inhaled glucocorticoid therapy.
• Patients suffering from uncontrollable comorbid diseases, including but not limited to symptomatic congestive heart failure, uncontrollable hypertension, unstable angina, active peptic ulcer or bleeding disorders.
• Pregnant or lactating women.
• Patients with a history of interstitial lung disease or non-infectious pneumonia. Subjects who have previously had drug-induced or radioactive non-infectious pneumonia but asymptomatic are allowed to enroll.
• Any life-threatening disease, physical condition or organ dysfunction according to the researchers' judgment may endanger the safety of the subject or put the clinical research at excessive risk.
• Any other conditinons that the investigator considers inappropriate for participation in this study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL	Anti-PD-1 Antibody Plus Chidamide and Rituximab	Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL

Primary Outcome Measures

Name	Time	Method
complete response rate	24 weeks
Objective remission rate	24 weeks
Disease Control Rate	24 weeks
Partial Remission Rate	24 weeks

Secondary Outcome Measures

Name	Time	Method
Progression-free Survival	2 years	PFS was defined as time from study registration to first disease progression or death whichever occurred first, otherwise subject data were censored at time last known disease free
Overall Survival	2 years	OS was defined as time from study registration to death, and otherwise censored at time last known alive
Percentage of Participants With Adverse Events (AEs)	Up to 30 days after the last cycle of per-protocol treatment and 90 days after last dose of anti-PD-1 antibody	Number of participants with adverse events occurring up to 30 days after the last administration are evaluated and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.01